202 related articles for article (PubMed ID: 32875998)
1. Controversies with testosterone therapy.
Khera M
Can J Urol; 2020 Aug; 27(S3):20-23. PubMed ID: 32875998
[TBL] [Abstract][Full Text] [Related]
2. Controversies in Testosterone Therapy.
Twitchell DK; Pastuszak AW; Khera M
Sex Med Rev; 2021 Jan; 9(1):149-159. PubMed ID: 33309270
[TBL] [Abstract][Full Text] [Related]
3. Testosterone Therapy and Cardiovascular Risk: A Critical Analysis of Studies Reporting Increased Risk.
Khera M; Miner M; Jaffe J; Pastuszak AW
J Sex Med; 2021 Jan; 18(1):83-98. PubMed ID: 33317996
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Morbidity and Mortality in Men - Findings From a Meta-analysis on the Time-related Measure of Risk of Exogenous Testosterone.
Fallara G; Pozzi E; Belladelli F; Corsini C; Boeri L; Capogrosso P; Montorsi F; Salonia A
J Sex Med; 2022 Aug; 19(8):1243-1254. PubMed ID: 35753891
[TBL] [Abstract][Full Text] [Related]
5. The Role of Testosterone Therapy in the Setting of Prostate Cancer.
Rodriguez KM; Pastuszak AW; Khera M
Curr Urol Rep; 2018 Jun; 19(8):67. PubMed ID: 29961247
[TBL] [Abstract][Full Text] [Related]
6. Testosterone Therapy After Prostate Cancer Treatment: A Review of Literature.
Natale C; Carlos C; Hong J; Khera M; Baum N; Raheem OA
Sex Med Rev; 2021 Jul; 9(3):393-405. PubMed ID: 33516741
[TBL] [Abstract][Full Text] [Related]
7. Voiding function improves under long-term testosterone treatment (TTh) in hypogonadal men, independent of prostate size.
Yassin A; Alwani M; Al-Zoubi RM; Aboumarzouk OM; Talib R; Nettleship J; Kelly D; Albaba B
Int Urol Nephrol; 2023 Jul; 55(7):1649-1658. PubMed ID: 37148486
[TBL] [Abstract][Full Text] [Related]
8. Testosterone and Cardiovascular Risk: Meta-Analysis of Interventional Studies.
Corona G; Rastrelli G; Di Pasquale G; Sforza A; Mannucci E; Maggi M
J Sex Med; 2018 Jun; 15(6):820-838. PubMed ID: 29803351
[TBL] [Abstract][Full Text] [Related]
9. Is testosterone a friend or a foe of the prostate?
Jannini EA; Gravina GL; Morgentaler A; Morales A; Incrocci L; Hellstrom WJ
J Sex Med; 2011 Apr; 8(4):946-55. PubMed ID: 21457469
[TBL] [Abstract][Full Text] [Related]
10. Testosterone therapy in prostate cancer: is it still a controversy?
Bart AS; Van Hoof A; Badre-Hume R; Selvarajah J; Robillard K; Albala DM
Curr Opin Urol; 2022 Nov; 32(6):598-606. PubMed ID: 36081393
[TBL] [Abstract][Full Text] [Related]
11. Testosterone treatment and change of categories of the International prostate symptom score (IPSS) in hypogonadal patients: 12 years prospective controlled registry study.
Yassin A; Kelly D; Nettleship J; Talib R; Al-Zoubi RM; Aboumarzouk OM; Albaba B
Aging Male; 2023 Dec; 26(1):2220567. PubMed ID: 37287273
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality.
Saad F; Caliber M; Doros G; Haider KS; Haider A
Aging Male; 2020 Mar; 23(1):81-92. PubMed ID: 30782054
[No Abstract] [Full Text] [Related]
13. Hypogonadal men with moderate-to-severe lower urinary tract symptoms have a more severe cardiometabolic risk profile and benefit more from testosterone therapy than men with mild lower urinary tract symptoms.
Saad F; Doros G; Haider KS; Haider A
Investig Clin Urol; 2018 Nov; 59(6):399-409. PubMed ID: 30402573
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular impact of testosterone therapy for hypogonadism.
Rastrelli G; Dicuio M; Reismann Y; Sforza A; Maggi M; Corona G
Expert Rev Cardiovasc Ther; 2018 Sep; 16(9):617-625. PubMed ID: 30099911
[TBL] [Abstract][Full Text] [Related]
15. Hypogonadism: Therapeutic Risks, Benefits, and Outcomes.
Sigalos JT; Pastuszak AW; Khera M
Med Clin North Am; 2018 Mar; 102(2):361-372. PubMed ID: 29406064
[TBL] [Abstract][Full Text] [Related]
16. Testosterone does not affect lower urinary tract symptoms while improving markers of prostatitis in men with benign prostatic hyperplasia: a randomized clinical trial.
Rastrelli G; Cipriani S; Lotti F; Cellai I; Comeglio P; Filippi S; Boddi V; Della Camera PA; Santi R; Boni L; Nesi G; Serni S; Gacci M; Maggi M; Vignozzi L
J Endocrinol Invest; 2022 Jul; 45(7):1413-1425. PubMed ID: 35298833
[TBL] [Abstract][Full Text] [Related]
17. Alternatives to Testosterone Therapy: A Review.
Lo EM; Rodriguez KM; Pastuszak AW; Khera M
Sex Med Rev; 2018 Jan; 6(1):106-113. PubMed ID: 29174957
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and Treatment of Testosterone Deficiency: Updated Recommendations From the Lisbon 2018 International Consultation for Sexual Medicine.
Morgentaler A; Traish A; Hackett G; Jones TH; Ramasamy R
Sex Med Rev; 2019 Oct; 7(4):636-649. PubMed ID: 31351915
[TBL] [Abstract][Full Text] [Related]
19. Trends in Testosterone Therapy use in Prostate Cancer Survivors in the United States.
Chen T; Li S; Eisenberg ML
J Sex Med; 2021 Aug; 18(8):1346-1353. PubMed ID: 34303630
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores.
Corona G; Rastrelli G; Morgentaler A; Sforza A; Mannucci E; Maggi M
Eur Urol; 2017 Dec; 72(6):1000-1011. PubMed ID: 28434676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
